Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors
Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr virus (EBV)-associated Solid Tumors
Experimental Tumor
DRUG: Chidamide
objective response rate（ORR）, the total proportion of patients with complete response（CR）and partial response（PR）, up to 2 years
Disease Control Rate （DCR）, the total proportion of patients with complete response（CR）, partial response（PR）and Stable Disease（SD）, up to 2 years|Duration of Response （DOR）, Time from first documented complete response (CR) or partial response (PR) until time of progression., up to 2 years|progression-free survival（PFS）, Time from treatment until disease progression or death, 2 years|overall survival（OS）, Time from treatment until death from any cause, 2 years
Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with recurrent and metastatic Epstein-Barr virus (EBV)-associated solid tumors.